Pharmacology And Safety Of Tetradecylthioacetic Acid (TTA): Phase-1 Study
| Effect | None |
| Trial Design | Cohort |
| Trial Length | 1-7 Days |
| Number of Subjects | 18 |
| Gender | Male |
| Age Range | 18-29, 30-44 |
| Body Types | Average |
7 days of supplementation with TTA showed no significant or consistent effects on liver enzymes, uric acid, CRP or other relevant safety parameters at doses of 200, 600, and 1000mg in otherwise healthy persons.
Total cholesterol, LDL, and triglycerides showed a nonsignificant trend to decrease while HDL and free fatty acids were not affected. Other health parameters were unaffected over the whole group.
TTA appears to be absorbed, although the bioavailability was not calculated and the rate of absorption was different between subjects. TTA is detectable in the blood following a week of supplement cessation, but not three weeks cessation.
